| Literature DB >> 26582633 |
Prue Cormie1, Benjamin Singh2, Sandi Hayes2, Jonathan M Peake2, Daniel A Galvão3, Dennis R Taaffe4, Nigel Spry5, Kazunori Nosaka3, Bruce Cornish2, Kathryn H Schmitz6, Robert U Newton7.
Abstract
Background Resistance exercise is emerging as a potential adjunct therapy to aid in the management of breast cancer-related lymphedema (BCRL). However, the mechanisms underlying the relationships between the acute and long-term benefits of resistance exercise on BCRL are not well understood. Purpose To examine the acute inflammatory response to upper-body resistance exercise in women with BCRL and to compare these effects between resistance exercises involving low, moderate, and high loads. The impact on lymphedema status and associated symptoms was also compared. Methods A total of 21 women, 62 ± 10 years old, with BCRL participated in the study. Participants completed low-load (15-20 repetition maximum [RM]), moderate-load (10-12 RM), and high-load (6-8 RM) exercise sessions consisting of 3 sets of 6 upper-body resistance exercises. Sessions were completed in a randomized order separated by a 7- to 10-day wash-out period. Venous blood samples were obtained to assess markers of exercise-induced muscle damage and inflammation. Lymphedema status was assessed using bioimpedance spectroscopy and arm circumferences, and associated symptoms were assessed using Visual Analogue Scales for pain, heaviness, and tightness. Measurements were conducted before and 24 hours after the exercise sessions. Results No significant changes in creatine kinase, C-reactive protein, interleukin-6, and tumor necrosis factor-α were observed following the 3 resistance exercise sessions. There were no significant changes in arm swelling or symptom severity scores across the 3 resistance exercise conditions. Conclusions The magnitude of acute exercise-induced inflammation following upper-body resistance exercise in women with BCRL does not vary between resistance exercise loads.Entities:
Keywords: breast cancer; inflammation; lymphedema; resistance exercise; weight training
Mesh:
Substances:
Year: 2015 PMID: 26582633 PMCID: PMC5739184 DOI: 10.1177/1534735415617283
Source DB: PubMed Journal: Integr Cancer Ther ISSN: 1534-7354 Impact factor: 3.279
Figure 1.Flow of participants throughout trial.
Participant Characteristics (n = 21).
| Characteristics | Mean ± SD or n (%) |
|---|---|
| Age (years) | 61.5 ± 10.1 |
| Body mass (kg) | 82.2 ± 16.2 |
| Body mass index (kg/m²) | |
| Normal (18.5-24.9) | 2 (9.1%) |
| Overweight (25-29.9) | 8 (36.4%) |
| Obese (≥30) | 12 (54.5%) |
| Presence of comorbidities[ | |
| 0 | 7 (31.8%) |
| 1 | 4 (18.2%) |
| 2 | 7 (31.8%) |
| 3+ | 4 (18.2%) |
| Time since cancer diagnosis (years) | 9.4 ± 8.9 |
| Cancer stage | |
| I | 4 (18.2%) |
| II | 5 (22.7%) |
| III | 4 (18.2%) |
| IV | 2 (9.1%) |
| Missing | 7 (31.8%) |
| Adjuvant treatment (yes) | |
| Radiotherapy | 17 (77.3%) |
| Chemotherapy | 16 (72.7%) |
| Hormone therapy (currently and/or previously) | 13 (59.1%) |
| Surgery (yes) | 21 (95.5%) |
| Full axillary clearance (yes) | 16 (72.7%) |
| Number of lymph nodes dissected | 16.6 ± 7.7 |
| Years since lymphedema diagnosis | 9.4 ± 8.9 |
| Lymphedema treatment in previous 3 months (yes) | 8 (36.4%) |
| Lymphedema severity[ | |
| Mild | 9 (40.9%) |
| Moderate | 4 (18.2%) |
| Severe | 9 (40.9%) |
| Currently physically active[ | 19 (86.4%) |
Abbreviation: SD, standard deviation.
Comorbidities include hypertension/high blood pressure, high cholesterol, cardiovascular disease or heart disease, diabetes, and osteoporosis.
According to the American Physical Therapy Association lymphedema criteria.[15]
Physically active defined as meeting the Australian national physical activity guidelines.[53]
Mean Perceived Exertion and Tolerability, as Well as the Loads Lifted, for the Low-, Moderate-, and High-Load Conditions.
| Low Load,[ | Moderate Load,[ | High Load,[ | |
|---|---|---|---|
| Perceived exertion (RPE scale)[ | 12.7 ± 1.9 | 12.6 ± 0.9 | 13.1 ± 1.8 |
| Tolerability (7-point Likert scale)[ | 6.4 ± 0.8 | 5.9 ± 1.5 | 6.4 ± 0.7 |
| Resistance exercise loads | |||
| Chest press (kg) | 10.8 ± 6.4 | 12.8 ± 7.4 | 14.7 ± 8.3 |
| Lat-pulldown (kg) | 13.2 ± 8.0 | 16.2 ± 9.5 | 19.0 ± 10.9 |
| Biceps curl (kg) | 2.2 ± 0.4 | 2.8 ± 0.6 | 3.5 ± 0.7 |
| Lateral raise (kg) | 1.7 ± 0.4 | 2.1 ± 0.5 | 2.6 ± 0.6 |
| Triceps extension (kg) | 3.4 ± 3.6 | 5.1 ± 5.5 | 6.5 ± 6.7 |
| Wrist curl (kg) | 1.9 ± 0.5 | 4.3 ± 3.5 | 3.2 ± 0.9 |
Abbreviation: RPE, Rating of Perceived Exertion.
The load lifted differed significantly between the 3 exercise conditions.
Perceived exertion assessed using a 6 (no exertion at all) to 20 (maximal exertion) scale.
Tolerability assessed using a 1 (strongly disagree) to 7 (strongly agree) scale in response to the statement, “I have found the exercise session to be tolerable.”
Lymphedema Status and Associated Symptom Severity Before and 24 Hours After Low-, Moderate-, and High-Load Conditions (Mean ± SD).
| Extent of Swelling | Symptom Severity | ||||
|---|---|---|---|---|---|
| BIS (L-Dex) | Circumference Difference[ | Pain (mm) | Heaviness (mm) | Tightness (mm) | |
| Low-load resistance exercise | |||||
| Pre-exercise (n = 20) | 15.19 ± 18.97 | 6.73 ± 5.79 | 0.35 ± 0.75 | 0.67 ± 1.18 | 0.75 ± 1.19 |
| 24 Hours postexercise (n = 20) | 12.87 ± 16.55 | 5.96 ± 6.11[ | 0.40 ± 0.88 | 0.68 ± 1.13 | 0.87 ± 1.31 |
| Mean change from pre-exercise to 24 hours postexercise (95% CI) | −2.51 (−7.22, 2.19) | −0.77 (−1.41, −0.13) | +0.04 (−0.07, 0.17) | +0.01 (−0.33, 0.33) | +0.12 (−0.17, 0.42) |
| Moderate-load resistance exercise | |||||
| Pre-exercise (n = 16) | 16.38 ± 23.00 | 8.13 ± 6.76 | 0.11 ± 0.14 | 0.78 ± 1.67 | 0.67 ± 1.23 |
| 24 Hours postexercise (n = 16) | 13.86 ± 19.25 | 6.93 ± 6.06 | 0.50 ± 1.58 | 1.22 ± 1.93 | 1.28 ± 2.35 |
| Mean change from pre-exercise to 24 hours postexercise (95% CI) | −2.51 (−7.22, 2.19) | −1.20 (–3.32, 0.92) | +0.38 (−0.55, 1.32) | +0.43 (−0.38, 1.25) | +0.60 (−0.34, 1.55) |
| High-load resistance exercise | |||||
| Pre-exercise (n = 21) | 16.71 ± 18.89 | 5.59 ± 6.24 | 0.40 ± 0.87 | 0.98 ± 1.60 | 1.18 ± 1.86 |
| 24 Hours postexercise (n = 21) | 14.16 ± 16.85 | 5.49 ± 5.26 | 0.26 ± 0.52 | 0.73 ± 1.49 | 0.65 ± 1.44[ |
| Mean change from pre-exercise to 24 hours postexercise (95% CI) | −2.54 (−5.23, 0.14) | −0.10 (−1.48, 1.28) | −0.13 (−0.33, 0.61) | −0.25 (−0.55, 0.03) | −0.52 (−0.93, −0.11) |
Abbreviations: SD, standard deviation; BIS, bioimpedance spectroscopy; CI, confidence interval.
Interlimb circumference difference.
Significantly different from pre-exercise (P = .02).
Significantly different from pre-exercise (P = .015).
Figure 2.Individual response in markers of muscle damage and inflammation presented as the mean change from pre-exercise to 24 hours postexercise for low-, moderate-, and high-load conditions.a
a*Denotes extreme outliers (≥3 × interquartile range); ○ denotes mild outliers (≥1.5 × interquartile range).
Inflammatory Marker Response, Including CK, CRP, TNF-α, and IL-6, to the Resistance Exercise Conditions From Pre-exercise to 24 Hours Postexercise.
| Low Load, Mean ± SD | Moderate Load, Mean ± SD | High Load, Mean ± SD | |
|---|---|---|---|
| CK (U/L) | |||
| Pre-exercise | 85.80 ± 45.95 | 98.07 ± 76.15 | 83.52 ± 54.06 |
| Change from pre-exercise to 24 hours postexercise (95% CI) | 0.70 (−9.29, 10.69) | 1.07 (−5.73, 7.87) | 5.89 (−3.29, 15.08) |
| CRP (ng/mL) | |||
| Pre-exercise | 7.56 ± 5.36 | 5.97 ± 5.63 | 6.69 ± 5.79 |
| Change from pre-exercise to 24 hours postexercise (95% CI) | −0.30 (−1.39, 0.78) | 0.66 (−0.57, 1.90) | −0.40 (−1.65, 0.84) |
| TNF-α (pg/mL) | |||
| Pre-exercise | 10.13 ± 6.81 | 8.65 ± 8.37 | 10.06 ± 6.97 |
| Change from pre-exercise to 24 hours postexercise (95% CI) | 0.67 (−0.50, 1.84) | 0.04 (−2.73, 2.83) | −0.36 (−1.66, 0.92) |
| IL-6 (ng/mL) | |||
| Pre-exercise | 2.23 ± 4.29 | 2.58 ± 5.59 | 2.65 ± 5.42 |
| Change from pre-exercise to 24 hours postexercise (95% CI) | 0.58 (−0.48, 1.65) | 0.64 (−0.27, 1.56) | −0.05 (−0.51, 0.39) |
Abbreviations: CK, creatine kinase; CRP, C-reactive protein; TNF, tumor necrosis factor; IL-6, interleukin-6; SD, standard deviation; CI, confidence interval.